Subscribe to Updates
Subscribe to our newsletter and never miss our latest news
Subscribe my Newsletter for New Posts & tips Let's stay updated
Author: Editor
Premium Membership Required
You must be a Premium member to access this content.
Premium Membership Required
You must be a Premium member to access this content.
Premium Membership Required
You must be a Premium member to access this content.
Premium Membership Required
You must be a Premium member to access this content.
Signage is seen at the 2019 Deadline Contenders Hulu Reception at Paramount Theater on the Paramount Studios lot on April 07, 2019 in Hollywood, California.Rachel Murray | Getty ImagesDisney has agreed to pay Comcast $438.7 million for its stake in the streaming service Hulu, concluding a years-long appraisal process.In 2023 Disney announced it intended to buy Comcast’s 33% stake in Hulu. At the time, Disney paid $8.6 billion, which reflected Hulu’s guaranteed minimum value of $27.5 billion. The two companies had agreed on that floor in 2019.Disney’s announcement came as no surprise as it was widely reported by CNBC and…
U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. testifies before the Senate Committee on Appropriations hearing on the Department of Health and Human Services budget, on Capitol Hill in Washington, D.C., U.S., May 20, 2025. Ken Cedeno | ReutersHealth and Human Services Secretary Robert F. Kennedy Jr. on Monday said he is “retiring” all 17 members of a crucial government panel of vaccine advisors, a shocking step that could help to sow doubts about immunizations in the U.S.”A clean sweep is needed to re-establish public confidence in vaccine science,” Kennedy said in an opinion piece in the…
Premium Membership Required
You must be a Premium member to access this content.
Premium Membership Required
You must be a Premium member to access this content.
The Food and Drug Administration on Monday approved Merck’s shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca.The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter and lasts through the spring. Merck said in a release that it expects orders for the shot to begin in July, with shipments delivered before the virus starts to spread widely.The approval gives doctors…
Premium Membership Required
You must be a Premium member to access this content.